Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
Regeneron Pharmaceuticals Inc. pages available for free this week:
- Income Statement
- Statement of Comprehensive Income
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Solvency Ratios
- Analysis of Geographic Areas
- Price to FCFE (P/FCFE)
- Dividend Discount Model (DDM)
- Return on Assets (ROA) since 2005
- Current Ratio since 2005
- Total Asset Turnover since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Regeneron Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Long-term Activity Ratios (Summary)
Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
- Net Fixed Asset Turnover
- The net fixed asset turnover ratio demonstrates a rising trend from 2.82 in the first quarter of 2021, reaching a peak of 4.64 in the first quarter of 2022. Following this peak, there is a noticeable decline over subsequent periods, with the ratio decreasing steadily to 2.85 by the third quarter of 2025. This suggests that the efficiency in utilizing fixed assets to generate sales improved significantly in early 2021 but weakened gradually from 2022 onward.
- Total Asset Turnover
- The total asset turnover ratio shows an initial increase from 0.52 in the first quarter of 2021 to a high of 0.63 in both the fourth quarter of 2021 and the first quarter of 2022. After this, a consistent decline occurs, lowering the ratio to 0.35 by the third quarter of 2025. This declining trend indicates diminishing effectiveness in using total assets to generate revenue over the latter periods.
- Equity Turnover
- Equity turnover starts at 0.77 in the first quarter of 2021, climbs to a maximum of 0.86 by the fourth quarter of 2021, and then enters a downward trajectory falling to 0.46 by the third quarter of 2025. This gradual reduction highlights decreasing sales generated per unit of equity invested, reflecting less efficient use of equity in later periods.
Net Fixed Asset Turnover
| Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||
| Revenues | |||||||||||||||||||||||||
| Property, plant, and equipment, net | |||||||||||||||||||||||||
| Long-term Activity Ratio | |||||||||||||||||||||||||
| Net fixed asset turnover1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Net Fixed Asset Turnover, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
1 Q3 2025 Calculation
Net fixed asset turnover
= (RevenuesQ3 2025
+ RevenuesQ2 2025
+ RevenuesQ1 2025
+ RevenuesQ4 2024)
÷ Property, plant, and equipment, net
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The company’s quarterly financial data reveals several notable trends over the observed periods.
- Revenues
- Revenues exhibit considerable volatility across quarters, with fluctuations that do not follow a consistent seasonal pattern. Starting at approximately $2.53 billion in the first quarter of 2021, revenues spike sharply to about $5.14 billion in the second quarter of 2021 before declining in subsequent quarters. From early 2022 through the end of 2023, revenues generally remain in a range between $2.85 billion and $3.43 billion, indicating stabilization at a moderately lower level compared to the peak in mid-2021. Into 2024 and 2025, revenues show an upward trend reaching peaks over $3.7 billion but again exhibit some quarter-to-quarter variability, finishing with over $3.75 billion in the third quarter of 2025. The data reflects periods of significant growth interspersed with declines, which may suggest fluctuations in product demand, pricing, or market conditions.
- Property, Plant, and Equipment, Net (PP&E)
- Net PP&E demonstrates a steady and consistent growth trajectory over the entire period. Values increase from approximately $3.26 billion in the first quarter of 2021 to over $5 billion by the third quarter of 2025. This continuous increase in fixed assets indicates ongoing investment in capital infrastructure, suggesting expansion activities or modernization efforts. The steady accumulation of PP&E may contribute to capacity enhancement or support for new product lines or R&D activities.
- Net Fixed Asset Turnover Ratio
- The net fixed asset turnover ratio, which measures efficiency in using fixed assets to generate revenue, shows a declining trend throughout the timeline. The ratio peaks around 4.64 in early 2022 but gradually declines to approximately 2.85 by the third quarter of 2025. This downward trend suggests that revenue growth is not keeping pace with the growth in fixed assets. The decrease in turnover ratio could indicate diminishing returns on recent capital investments, underutilization of new assets, or a shift in the company's operational efficiency.
In summary, while the company continues to invest heavily in property, plant, and equipment, revenue performance has been uneven with intermittent growth and decline. The declining fixed asset turnover ratio points to a relative decrease in asset utilization efficiency, which may warrant further evaluation of capital expenditure effectiveness and operational strategies.
Total Asset Turnover
| Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||
| Revenues | |||||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||||
| Long-term Activity Ratio | |||||||||||||||||||||||||
| Total asset turnover1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Total Asset Turnover, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
1 Q3 2025 Calculation
Total asset turnover
= (RevenuesQ3 2025
+ RevenuesQ2 2025
+ RevenuesQ1 2025
+ RevenuesQ4 2024)
÷ Total assets
= ( + + + )
÷ =
2 Click competitor name to see calculations.
- Revenue Trends
- Revenues displayed considerable volatility throughout the observed periods. Initial quarters showed a notable increase from approximately 2.53 billion to over 5.1 billion US dollars, followed by fluctuations around the 3 billion to 3.7 billion range in subsequent years. While revenues experienced periodic declines, there was a general recovery trend towards the later quarters, with values approaching or exceeding previous highs, peaking near 3.78 billion US dollars before a slight decrease in the final period.
- Total Assets Evolution
- Total assets showed a consistent upward trajectory across all periods. Starting around 17.77 billion US dollars, total assets increased steadily to exceed 40 billion US dollars by the end of the last quarter reviewed. This represents more than a twofold increase over the terms analyzed, indicating significant asset growth and likely corresponding investments or acquisitions.
- Total Asset Turnover Ratio
- The total asset turnover ratio exhibited a declining trend throughout the periods. Beginning at approximately 0.52, this ratio peaked near 0.63 in late 2021 but then steadily decreased to about 0.35 by the last quarter. This downward trend suggests that although assets have grown substantially, revenues have not increased proportionally, resulting in diminished efficiency in asset utilization over time.
- Insight Summary
- The company appears to have expanded its asset base significantly while experiencing fluctuating revenue levels. The declining total asset turnover ratio points to reduced efficiency in generating revenue from its assets. This may warrant a deeper evaluation of asset deployment strategies or market conditions impacting revenue generation. The fluctuating revenues combined with steady asset growth suggest potential challenges in converting new assets into proportional revenue increases.
Equity Turnover
| Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||
| Revenues | |||||||||||||||||||||||||
| Stockholders’ equity | |||||||||||||||||||||||||
| Long-term Activity Ratio | |||||||||||||||||||||||||
| Equity turnover1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Equity Turnover, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
1 Q3 2025 Calculation
Equity turnover
= (RevenuesQ3 2025
+ RevenuesQ2 2025
+ RevenuesQ1 2025
+ RevenuesQ4 2024)
÷ Stockholders’ equity
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The financial data reveals several notable trends in the quarterly performance metrics over the observed periods.
- Revenues
- Revenue figures demonstrate a fluctuating pattern without a consistent growth trajectory. Initial quarters show a notable increase from the first to second quarter of 2021, followed by volatility through 2022 and 2023. Peaks occur intermittently, such as in the second and third quarters of 2024, with values approaching 3.7 to 3.8 billion USD. However, there are also periods of decline, including in the early quarters of 2023 and 2025. Overall, the revenue trend highlights cyclical behavior with no clear, sustained upward or downward momentum.
- Stockholders’ Equity
- Stockholders’ equity exhibits a strong and steady upward trend throughout the entire timeframe. Beginning at approximately 11.98 billion USD, equity increases consistently across quarters, surpassing 30.95 billion USD by the latest reported period. This steady accumulation of equity indicates ongoing value retention and capital growth, reflecting positively on the company’s financial stability and reinvestment strategy.
- Equity Turnover Ratio
- The equity turnover ratio shows a declining trend over the periods examined. Starting at 0.77 in the first quarter of 2021, the ratio gradually decreases to approximately 0.46 by the third quarter of 2025. This declining ratio suggests that the company is generating less revenue per unit of equity over time, which may imply reduced efficiency in utilizing equity to drive revenues or a shift in business dynamics affecting turnover.
In summary, the data portrays a company with growing equity but facing challenges in maintaining consistent revenue growth and sustaining efficiency in equity utilization. While equity strength implies robust capital foundation, the lowering equity turnover ratio alongside fluctuating revenues may warrant further strategic review to enhance operational performance and revenue generation relative to invested equity.